CorVista Device to Diagnose PH Gets FDA Breakthrough Designation
The U.S. Food and Drug Administration (FDA) granted breakthrough device designation to the CorVista System, a point-of-care diagnostic tool that aims to use non-invasive tests and machine learning to help diagnose pulmonary hypertension and other cardiovascular disorders. The designation gives CorVista Health, the system’s developer, certain benefits aimed…